Clinical trial
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
NCT00355849 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00355849 |
|---|---|
| Title | Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes |
| Official title | A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients With Type 2 Diabetes Treated With Once-Daily Insulin Glargine |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Alkermes, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Human Insulin Inhalation Powder, Insulin Glargine |
| Enrollment | 555 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Jul 25, 2006 |
| Last update posted | Sep 16, 2019 |
| Countries | Brazil, Canada, Germany, India, Israel, Puerto Rico, Russia, South Africa, South Korea, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: